Abstract: TH-PO904
A Prospective Single-Center Study on Desidustat, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), in the Management of Anemia in Dialysis-Dependent CKD
Session Information
- Anemia and Iron Metabolism
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 200 Anemia and Iron Metabolism
Author
- Kumar Narayana, Arun, Apollo Hospital Seshadripuram, Bengaluru, Karnataka, India
Background
Erythropoietin analogous is the backbone of the treatment of dialysis-dependent CKD –Anemia. Recently in India, Desidustat (Oxemia®) a HIF PHI approved by DCGI in dialysis-dependent and Non dialysis-dependent CKD Anemia. The current study enroutes the outcome of the usage of desidustat in DD-CKD Anemia patients.
Methods
We analyzed data of patients who were receiving Desidustat 100 mg thrice weekly for correction of Anemia at our center. Patients were followed up regularly for Anemia parameters.
Results
In the current study, we enrolled data from 85 patients at our center. The majority of 61 (71.7%) were male, and 24 (28.2%) were female. The mean age of participants was 51.27±14 years. The majority, 66 (77.6%), belong to the middle socioeconomic background. All the patients analyzed received three-time maintenance hemodialysis at our center. Patients with ESRD 71 (83.5%), hypertension 83 (97.6%), diabetic nephropathy 42 (49.4%), PVD 3 (3.5%), Alport syndrome 1 (1.1%), and CVD 1 (1.1%). The baseline serum creatinine of the patients was 6.4±1.5 mg/dl. Serum Iron 29.51±7.94, TSAT 25.06 ± 6.9, and Serum Ferritin 89.34 ± 39.19. In the present study, out of 85 patients, 63 (74.1%) responded with the treatment of anemia, while 22 (25.6%) showed a low rise in Hb with desidustat treatment, as shown in figure 1. In the present study, out of 85 patients, 10 (11.7%) underwent renal transplantation and 3 (3.5%) expired. The reason for low Hb in 22 patients can be due to iron depletion. Gastrointestinal ADRs were observed with Desidustat therapy, which was treated appropriately.
Conclusion
The treatment of dialysis-dependent CKD anemia with Desidustat showed a promising response rate. Ensuring adequate iron repletion is crucial for optimizing the response to HIF-PHI treatment